What is the ROE (Return on Equity) of Biotron this year?
The ROE of Biotron this year is 14.08 undefined.
Biotron ROE 2025
Biotron ROE
14.08
Ticker
BIT.AX
ISIN
AU000000BIT4
WKN
602346
In 2025, Biotron's return on equity (ROE) was 14.08, a -1,379.17% increase from the -1.1 ROE in the previous year.
Biotron Aktienanalyse
What does Biotron do?
Biotron Ltd is a company that focuses on the research and development of antiviral drugs. The company was founded in 2000 by Dr. Michelle Miller, who previously worked as a senior researcher in the field of antiviral drug development at a leading pharmaceutical company. Biotron's main business is the development of drugs used to treat viral diseases such as HIV/AIDS, hepatitis B and C, influenza, and Ebola. The company focuses on the development of so-called direct-acting antiviral drugs, which target the virus itself and inhibit its replication. Biotron has made significant progress in the development of such drugs in recent years and currently has several drugs in clinical development. The company works closely with universities, research institutions, and other companies to advance its research and development program. Biotron's business model is based on collaboration with other companies in the field of antiviral drug development. The company works closely with other pharmaceutical companies, hospitals, and government agencies to share its research findings and technologies and bring its drugs to market. The company has two main divisions: research and development, and production and distribution. In the research and development division, Biotron focuses on the development of new drugs that target viruses. The production and distribution division encompasses the production and marketing of these drugs once they are approved for use. As part of its research and development work, Biotron has developed several promising products. One of them is BIT225, a drug used to treat hepatitis C. BIT225 is a direct-acting antiviral drug that targets a specific protein in the virus membrane and inhibits its replication. Another promising product from Biotron is BIT571, a drug used to treat influenza. BIT571 targets a specific type of virus known as Liana or influenza hemagglutinin virus. It has been shown that BIT571 has potent antiviral activity against this type of virus. In addition to BIT225 and BIT571, there are other drugs in clinical development at Biotron. Overall, Biotron has an extensive portfolio of antiviral drugs in various stages of clinical development. In recent years, Biotron has also made significant progress in the production and marketing of its drugs. The company has formed partnerships with other companies in the pharmaceutical manufacturing industry to ensure that its drugs can be produced and brought to market on a large scale. In summary, Biotron Ltd is an emerging company in the field of antiviral drug development. The company has made significant progress in the development of new drugs in recent years and works closely with other companies and research institutions to expand its portfolio. With its promising pipeline of antiviral drugs and strong partnerships with other companies, Biotron has the potential to become a major player in the pharmaceutical industry in the coming years. Biotron ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Biotron's Return on Equity (ROE)
Biotron's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Biotron's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Biotron's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Biotron’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Biotron stock
How has the Return on Equity (ROE) of Biotron developed compared to the previous year?
The ROE of Biotron has increased by -1,379.17% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Biotron?
A high ROE indicates that Biotron generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Biotron?
A low ROE can indicate that Biotron is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Biotron affect the company?
A change in ROE (Return on Equity) of Biotron can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Biotron?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Biotron?
Some factors that can influence Biotron's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Biotron pay?
Over the past 12 months, Biotron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biotron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Biotron?
The current dividend yield of Biotron is .
When does Biotron pay dividends?
Biotron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biotron?
Biotron paid dividends every year for the past 0 years.
What is the dividend of Biotron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biotron located?
Biotron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotron from 2/21/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 2/21/2025.
When did Biotron pay the last dividend?
The last dividend was paid out on 2/21/2025.
What was the dividend of Biotron in the year 2024?
In the year 2024, Biotron distributed 0 AUD as dividends.
In which currency does Biotron pay out the dividend?
The dividends of Biotron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotron
Our stock analysis for Biotron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
